Crinetics Pharmaceuticals Inc expected to post a loss of 81 cents a share - Earnings Preview

Crinetics Pharmaceuticals

08/05/2024 03:23

* Crinetics Pharmaceuticals Inc  CRNX.OQ   CRNX.O  is
expected
to show a fall in quarterly revenue when it reports  results on
May 9 for the period ending March 31 2024
    * The San Diego California-based  company is expected to
report a
90.5% decrease in revenue to $255.56 thousand from $2.68 million
a year ago, according to the mean estimate from 9 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Crinetics
Pharmaceuticals Inc
is for a loss of 81 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 13 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Crinetics
Pharmaceuticals Inc is $57.00​, above​ its last closing price
of $47.66. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.91       -0.86      -0.90     Missed  -4.4
 Sep. 30 2023  -0.87       -0.86      -1.01     Missed  -17.6
 Jun. 30 2023  -0.88       -0.86      -0.94     Missed  -9.6​
 Jan. 1 0001   -0.82       -0.81      -0.85     Missed  -4.7
 ​​Dec.        -0.83       -0.82      -0.84     Missed  -2.2
 31 2022                                                
 Sep. 30 2022  -0.84       -0.83      -0.78     Beat    6.2​
 Jun. 30 2022  -0.68       -0.67      -0.81     Missed  -20.3
 Mar. 31 2022  -0.57       -0.58      -0.71     Missed  -22.4
 This summary was machine generated May 8 at 02:22 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)